Brand names: RAPIBLYK
12.1 Mechanism of Action RAPIBLYK is a selective beta-1-adrenoreceptor antagonist that inhibits the positive chronotropic effects of the catecholamines, epinephrine and norepinephrine, on the heart, where beta-1-receptors are predominantly located. Landiolol does not exhibit any membrane-stabilizing activity or intrinsic sympathomimetic activity at the approved recommend dosage in vitro.
Contraindications
4 documented side effects by frequency
No community discussions found for LANDIOLOL yet.
Every figure on this page links back to its primary source. See data sources for full provenance.
0 available comparisons
No comparisons yet.
Dosage Forms
Tablet
Route
Intravenous